Boule receives CE mark according to IVDR Class B for two product lines
Trading of subscription rights commences Tuesday 15 November
Boule Diagnostics publishes prospectus in connection with its Rights Issue
Boule Diagnostics (publ) Interim report January–September 2022
Boule Diagnostics – Invitation to presentation of the interim report Q3 2022
Bulletin from the extraordinary general meeting in Boule Diagnostics on November 1, 2022
Boule Diagnostics – Nomination Committee for the 2023 Annual General Meeting
Boule sets up contract manufacturing of reagents in India
Boule Diagnostics resolves on a fully secured preferential rights issue of approximately SEK 150 million
Clinical Diagnostic Solutions has been issued a Notice of Inspectional Observations by FDA
Cision will store the added information in order to continuously be able to send you the information you’ve chosen to subscribe to. Read more about how Cision process personal data.
Search
Search on the page